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Down syndrome (DS) is caused by trisomy of human chromosome 21 (HSA21). Individuals with DS 
present craniofacial abnormalities including an undersized, dismorphic mandible leading to difficulty with 
eating, breathing, and swallowing. Using the Ts65Dn DS mouse model (three copies of ~50% HSA21 
homologs), we have traced the mandibular deficit to a neural crest cell (NCC) deficiency and reduction in 
first pharyngeal arch (PA1 or mandibular precursor) size at embryonic day 9.5. At E9.5, Dyrk1A, a 
triplicated DS candidate gene, is overexpressed and may cause the NCC and PA1 deficits. We 
hypothesize that treatment of pregnant Ts65Dn mothers with Epigallocatechin gallate (EGCG), a known 
Dyrk1A inhibitor, will correct NCC deficits and rescue the undersized PA1 in trisomic E9.5 embryos. To 
test our hypothesis, we treated pregnant Ts65Dn mothers with EGCG from either E7-E8 or E0-E9.5. Our 
preliminary study found an increase in PA1 volume and NCC number in trisomic E9.5 embryos after 
treatment, but observed differences between treatment regimens. Differential gene expression was also 
quantified in trisomic treated embryos. This preliminary data suggests EGCG treatment has the potential 
to rescue the mandibular phenotype caused by trisomy. These findings provide preclinical testing for a 
potential therapy for craniofacial disorders linked to DS. 
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